CANCER:

Pancreatic Ductal Adenocarcinoma

Related cancers:

‹

Pancreatic Cancer (278)

Pancreatic Adenocarcinoma (43)

Pancreatic Cancer (278)

Pancreatic Adenocarcinoma (43)

›

GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials Sci Rep - 1 week
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria Lancet Oncol - 3 weeks
PD-L1 expression PD-L1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab + trametinib Sensitive: C3 – Early Trials Lancet Oncol - 3 weeks
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	SBP-101 Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine + capecitabine Sensitive: B - Late Trials
CCL11 overexpression CCL11 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	tertomotide Sensitive: B - Late Trials
No biomarker No biomarker	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	CEND-1 Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label
ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label
HGF-H HGF-H	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials
MSI-L/dMMR MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation + BRCA2 mutation BRCA1 mutation + BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
FANCF mutation FANCF mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
MSH2 mutation MSH2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
DDR DDR	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C3 – Early Trials
C3M/PRO-C3 ratio elevation C3M/PRO-C3 ratio elevation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PEGPH20 Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	leucovorin calcium Resistant: C3 – Early Trials
GATA6 underexpression GATA6 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	5-fluorouracil Resistant: C3 – Early Trials
GATA6 expression GATA6 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials
LAMC2 overexpression LAMC2 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Resistant: C3 – Early Trials
ATM mutation ATM mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine + durvalumab + CP-675206 Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials
ATP1B1-NRG1 fusion ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	afatinib Sensitive: C4 – Case Studies
APP-NRG1 fusion APP-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	afatinib Sensitive: C4 – Case Studies
FGFR1 T141R FGFR1 T141R	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	crizotinib Resistant: C4 – Case Studies
FGFR1 T141R FGFR1 T141R	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	alectinib Sensitive: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	lorlatinib Sensitive: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Resistant: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	alectinib Resistant: C4 – Case Studies
MSI-H/dMMR + TMB-H + PD-L1 overexpression MSI-H/dMMR + TMB-H + PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies
TLE2 overexpression TLE2 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gemcitabine Sensitive: D – Preclinical
KRAS mutation KRAS mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BAL3833 Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GANT1 Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	GANT61 Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	Hedgehog cell-signalling pathway inhibitor Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cyclopamine Sensitive: D – Preclinical
ANIB1 overexpression ANIB1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	sonidegib Sensitive: D – Preclinical
ASS1 underexpression ASS1 underexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	panobinostat + pegargiminase Sensitive: D – Preclinical
TMB-L TMB-L	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	trametinib + Torin1 Sensitive: D – Preclinical
MUC1 overexpression MUC1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	BBI608 Sensitive: D – Preclinical
TP53 mutation TP53 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FL118 Sensitive: D – Preclinical
DDX5 overexpression DDX5 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FL118 Sensitive: D – Preclinical
GLI1 expression GLI1 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	sonidegib Sensitive: D – Preclinical
SIRT1 overexpression SIRT1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	gefitinib Sensitive: D – Preclinical
BRCA mutation BRCA mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PARP inhibitor Sensitive: D – Preclinical
KRAS G12D + Chr del(9)(p21) KRAS G12D + Chr del(9)(p21)	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	palbociclib Resistant: D – Preclinical
CD276 expression CD276 expression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	B7H3-targeted CAR-T immunotherapy Sensitive: D – Preclinical
SLC3A2-NRG1 fusion SLC3A2-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MM-121 Sensitive: D – Preclinical
ATP1B1-NRG1 fusion ATP1B1-NRG1 fusion	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	MM-121 Sensitive: D – Preclinical
KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	sotorasib + selinexor Sensitive: D – Preclinical
KRAS G12C KRAS G12C	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	selinexor + MRTX1257 Sensitive: D – Preclinical

Pancreatic Ductal Adenocarcinoma

Associations(61)

Associations
(61)